| Display title | Chemistry:Pralatrexate |
| Default sort key | Pralatrexate |
| Page length (in bytes) | 9,177 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 544943 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>Carolyn |
| Date of page creation | 14:38, 26 June 2023 |
| Latest editor | imported>Carolyn |
| Date of latest edit | 14:38, 26 June 2023 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Pralatrexate, sold under the brand name Folotyn, is a medication used for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL).
Pralatrexate was approved for medical use in the United States in September 2009, as the first treatment for Peripheral T-cell Lymphoma (PTCL), an often... |
